Arintra Cuts Coding Costs by Nearly One-Third for Customers, Driving Industry-Leading Retention and 8X Revenue Growth

The Company’s Outcomes-First Approach Drove 13 Enterprise Deals in 100 Days as Financial Pressures Intensify for Providers

SAN FRANCISCO--(BUSINESS WIRE)--Arintra, the leading GenAI-native autonomous medical coding platform for healthcare organizations, today announced it finished 2025 with eight times year-over-year revenue growth, driven by growing adoption across health systems and physician groups. Over the past year, Arintra has increased its monthly coding volume more than five times and now autonomously codes claims across a majority of ambulatory care specialities, including primary care, cardiology, and pediatrics, as well as urgent care, the emergency department, inpatient rounding, and diagnostic specialties such as radiology and pathology.

As healthcare organizations' margins continue to thin and reimbursement models shift, Arintra’s traction and rapid adoption highlight the growing need for transparent, audit-ready coding that seamlessly integrates into existing workflows to strengthen their organizations' financial performance and long-term stability. Against this backdrop, Arintra signed 13 enterprise deals in just 100 days, underscoring the demand for AI solutions that deliver measurable value quickly. Because Arintra deeply integrates directly with existing EHR systems, such as Epic and athenahealth, customers are typically live and achieving measurable returns within four to six weeks.

Every Arintra partnership starts with a proof-of-value phase, giving customers the opportunity to validate results before expanding to an enterprise deployment. This approach has proven effective, with 100% of customers moving from proof-of-value to deployments across multiple specialties. With this, Arintra’s customers are seeing an average revenue uplift of 5-8%, at least a 32% reduction in coding costs, and a 64% drop in pre–account receivable days. Together, these results translate to a typical return of more than 10 times their initial investment.

“We hear the same things over and over from health systems and provider groups. They’re expanding services, but financial pressures and administrative burdens are stretching their teams thin,” said Nitesh Shroff, Chief Executive Officer and Co-Founder of Arintra. “This is amplifying the need for AI solutions that can quickly and meaningfully improve efficiency across the board.”

“What’s driven our company's growth is that we are relentlessly focused on delivering measurable outcomes,” added Preeti Bhargava, Chief Technology Officer and Co-Founder of Arintra. “Prove value first, then scale. That’s the standard we’ll carry forward as we expand our reach deeper into the revenue cycle.”

Building on this outcomes-first philosophy, Arintra plans to expand its product roadmap in 2026 to support a broader set of revenue-cycle workflows, helping customers close financial gaps before and after coding, including solutions that support prior authorizations and denials. This news follows the company’s $21 million Series A in August 2025, as Arintra prepares to raise additional capital later this year.

For more information about Arintra or its autonomous coding platform, please visit arintra.com.

About Arintra

Arintra provides the industry's leading GenAI-native autonomous coding platform, enabling health systems and physician groups to get paid accurately and efficiently for the care they deliver, driving revenue assurance at scale. By combining cutting-edge AI with deep clinical expertise, Arintra autonomously codes charts with high accuracy, without human intervention. Unlike bolt-on tools, Arintra works directly within the EHR, ensuring seamless adoption with zero workflow changes or data integrity risk. Health systems use Arintra to unlock missed revenue due to coding gaps, documentation issues, and unchallenged denials - achieving 5%+ uplift in revenue, 64%+ reduction in pre-A/R days, and 43%+ fewer denials.